NO20001869D0 - Fremgangsmõte for behandling av Alzheimerssykdom - Google Patents

Fremgangsmõte for behandling av Alzheimerssykdom

Info

Publication number
NO20001869D0
NO20001869D0 NO20001869A NO20001869A NO20001869D0 NO 20001869 D0 NO20001869 D0 NO 20001869D0 NO 20001869 A NO20001869 A NO 20001869A NO 20001869 A NO20001869 A NO 20001869A NO 20001869 D0 NO20001869 D0 NO 20001869D0
Authority
NO
Norway
Prior art keywords
alzheimer
procedures
disease
treatment
Prior art date
Application number
NO20001869A
Other languages
English (en)
Other versions
NO20001869L (no
Inventor
David Robert Howlett
Davina Elizabeth Mitchell
Original Assignee
Boehringer Mannheim Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharm Corp filed Critical Boehringer Mannheim Pharm Corp
Publication of NO20001869D0 publication Critical patent/NO20001869D0/no
Publication of NO20001869L publication Critical patent/NO20001869L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
NO20001869A 1997-10-15 2000-04-11 FremgangsmÕte for behandling av Alzheimers sykdom NO20001869L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6236697P 1997-10-15 1997-10-15
PCT/US1998/021789 WO1999018794A1 (en) 1997-10-15 1998-10-15 Method for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
NO20001869D0 true NO20001869D0 (no) 2000-04-11
NO20001869L NO20001869L (no) 2000-06-14

Family

ID=22042015

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001869A NO20001869L (no) 1997-10-15 2000-04-11 FremgangsmÕte for behandling av Alzheimers sykdom

Country Status (16)

Country Link
US (1) US6358990B1 (no)
EP (1) EP1024697A4 (no)
JP (1) JP2001519364A (no)
KR (1) KR100573352B1 (no)
CN (1) CN1281334A (no)
AU (1) AU751526B2 (no)
BR (1) BR9814075A (no)
CA (1) CA2305262A1 (no)
HU (1) HUP0100024A3 (no)
IL (1) IL135584A (no)
NO (1) NO20001869L (no)
NZ (1) NZ504419A (no)
PL (1) PL339910A1 (no)
TR (1) TR200001018T2 (no)
WO (1) WO1999018794A1 (no)
ZA (1) ZA989365B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142175A1 (de) * 2001-10-09 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung von ß-Adrenozeptor-Agonisten zur Behandlung von neurodegenerativen Erkrankungen
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003092622A2 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
KR20140006111A (ko) * 2002-06-27 2014-01-15 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
EP1539140A4 (en) * 2002-06-27 2005-12-07 Sb Pharmco Inc CARVEDILOLHYDOBROMID
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
CN1991364A (zh) * 2005-12-26 2007-07-04 中国科学院上海生命科学研究院 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2008021552A2 (en) * 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
HRP20220401T3 (hr) 2008-02-14 2022-05-27 Eli Lilly And Company Nova vizualizacijska sredstva za detektiranje neurološke disfunkcije
CN103172643B (zh) * 2011-12-26 2016-03-02 中国医学科学院药物研究所 黄皮咔唑生物碱及其制备方法和其药物组合物与用途
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
US10111879B2 (en) 2013-06-27 2018-10-30 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
CA3192905A1 (en) * 2020-09-17 2022-06-23 Sui Rong Wayne CHEN Methods of treating and/or preventing alzheimer's disease with r-carvedilol

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
EP0275668B1 (en) * 1986-12-17 1992-09-30 Glaxo Group Limited Use of ketone derivatives in the treatment of cognitive disorders
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
JPH0558998A (ja) * 1991-09-06 1993-03-09 Taisho Pharmaceut Co Ltd カルバゾール誘導体
WO1996003377A1 (en) * 1994-07-27 1996-02-08 Sankyo Company, Limited Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors
FR2724933A1 (fr) * 1994-09-22 1996-03-29 Pf Medicament Nouveaux ethers aromatiques derives d'indoles utiles comme medicaments
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2731222A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
EP0823894A1 (en) * 1995-05-01 1998-02-18 University Of Pittsburgh Azocompounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition

Also Published As

Publication number Publication date
JP2001519364A (ja) 2001-10-23
CA2305262A1 (en) 1999-04-22
AU1089799A (en) 1999-05-03
IL135584A (en) 2005-12-18
PL339910A1 (en) 2001-01-15
WO1999018794A1 (en) 1999-04-22
US6358990B1 (en) 2002-03-19
NZ504419A (en) 2002-11-26
EP1024697A1 (en) 2000-08-09
CN1281334A (zh) 2001-01-24
HUP0100024A2 (hu) 2001-07-30
HUP0100024A3 (en) 2002-12-28
BR9814075A (pt) 2000-09-26
KR100573352B1 (ko) 2006-04-25
TR200001018T2 (tr) 2000-08-21
AU751526B2 (en) 2002-08-22
IL135584A0 (en) 2001-05-20
ZA989365B (en) 1999-04-15
NO20001869L (no) 2000-06-14
EP1024697A4 (en) 2007-05-02
KR20010031108A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
EP1043991A4 (en) TREATMENT OF ALZHEIMER DISEASE
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
NO995221D0 (no) Sulfonamider for behandling av endotelinmedierte sykdommer
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
EP1007048A4 (en) IDENTIFICATION OF AGENTS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE
FI953915A0 (fi) Dupuytrenin taudin lievittämiseen
NO981388D0 (no) Bedring av Dupuytrens sykdom
IL127146A0 (en) Transdermal propentofylline compositions for the treatment of alzheimer's disease
NO20010953D0 (no) En fremgangsmÕte for behandling av stafylokokkal sykdom
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
DE69825888D1 (de) Diagnostisches verfahren der alzheimer-erkrankung
AU1405899A (en) Treatment for alzheimer's disease
GB0011410D0 (en) Therapeutic combination for treating Alzheimer's disease
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
EP1181550A4 (en) METHODS OF IDENTIFYING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
GB0011408D0 (en) Therapeutic combination for treating Alzheimer's Disease
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
NO982562D0 (no) Sammensetning for behandling av smerte
NO952411D0 (no) Midler for behandling av metaboliske bensykdommer
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
GB9709416D0 (en) Methods for treatment of alzheimer's disease using azaspiranes
NO970127D0 (no) Topiske sammensetninger for behandling av hudsykdom
HUP0000570A3 (en) Use of 17 alpha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states